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Abstract
Type IA topoisomerase activities are essential for resolving DNA topological barriers via an
enzyme-mediated transient single strand DNA break. Accumulation of topoisomerase DNA
cleavage product can lead to cell death or genomic rearrangement. Many antibacterial and
anticancer drugs act as topoisomerase poison inhibitors that form stabilized ternary com-
plexes with the topoisomerase covalent intermediate, so it is desirable to identify such inhib-
itors for type IA topoisomerases. Here we report that organomercury compounds were
identified during a fluorescence based screening of the NIH diversity set of small molecules
for topoisomerase inhibitors that can increase the DNA cleavage product of Yersinia pestis
topoisomerase I. Inhibition of relaxation activity and accumulation of DNA cleavage product
were confirmed for these organomercury compounds in gel based assays of Escherichia
coli topoisomerase I. Hg(II), but not As(III), could also target the cysteines that form the mul-
tiple Zn(II) binding tetra-cysteine motifs found in the C-terminal domains of these bacterial
topoisomerase I for relaxation activity inhibition.Mycobacterium tuberculosis topoisomer-
ase I activity is not sensitive to Hg(II) or the organomercury compounds due to the absence
of the Zn(II) binding cysteines. It is significant that the type IA topoisomerases with Zn(II)
binding domains can still cleave DNA when interfered by Hg(II) or organomercury com-
pounds. The Zn(II) binding domains found in human Top3α and Top3βmay be potential tar-
gets of toxic metals and organometallic complexes, with potential consequence on genomic
stability and development.
Introduction
Type IA topoisomerases are present in most organisms to provide the capability of resolving
topological barriers that require passage of DNA strand(s) through an enzyme bridged
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single-strand DNA break [1, 2]. Bacterial topoisomerase I responsible for removal of excess
negative supercoiling from chromosomal DNA is the major type IA topoisomerase activity in
bacteria, with Escherichia coli topoisomerase I as the most extensively studied example. Accu-
mulation of bacterial topoisomerase I covalent intermediate formed between the enzyme and
cleaved DNA has been shown to be bactericidal through genetic studies of mutants defective in
DNA rejoining, thus validating bacterial topoisomerase I as an attractive novel target for dis-
covery of new antibacterial compounds to combat multi-drug resistant bacterial pathogens [3].
Topoisomerase poison inhibitors that inhibit the catalytic step of DNA rejoining by type IB
human topoisomerase I or type IIA human and bacterial topoisomerases are clinically impor-
tant anticancer and antibacterial agents [4]. Such topoisomerase poison inhibitors have the
advantage that a small number of topoisomerase cleavage complexes stabilized on the chromo-
some may be sufficient for initiation of bacterial cell death as shown for quinolones acting as E.
coli DNA gyrase poison inhibitors [5]. A fluorescence based assay adaptable for high through-
put screening was developed for identification of similar poison inhibitors for type IA topo-
isomerases that can increase the oligonucleotide cleavage product accumulation for bacterial
topoisomerase I [6]. We report here that during assay development and pilot screening of NIH
Diversity Set I compounds against Yersinia pestis topoisomerase I, organomercury compounds
were identified as assay hits. Results shown here from additional biochemical experiments
demonstrated that organomercury compounds and mercury chloride target the cysteines pres-
ent in the C-terminal domains of E. coli and Y. pestis topoisomerase I for inhibition of relaxa-
tion activity. These results have significant implications both for the discovery of bacterial
topoisomerase I inhibitors, and the potential vulnerability of human type IA topoisomerases to
inhibition by toxic metal and organometallic compounds.
Materials and Methods
Topoisomerase Enzymes
Recombinant Y. pestis, E. coli andM. tuberculosis DNA topoisomerase I enzymes were express-
ed in E. coli and purified with previously described procedures [7–9].
Compounds
NIH diversity set I (1990 compounds with information on the set available in http://dtp.nci.
nih.gov/branches/dscb/diversity_explanation.html) and individual compounds from the set
were provided by the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov). Individual
compounds were suspended in dimethyl sulfoxide (DMSO) at a concentration of 40 mM. The
compound solutions were stored at -30°C as working solutions or at -80°C for long term.
Fluorescence assay for increase in bacterial topoisomerase I cleavage
product
The oligonucleotide substrate with sequence (5’-GTTATGCAATGCGCTTTGGGCAAAC
CAAGAGAGCATAAC-3’) was designed to produce an increase in fluorescence signal with a
higher level of bacterial topoisomerase I cleavage. Fluorescence emission from a fluorophore
placed at the 5’-end is limited by the presence of a quencher at the 3’-end due to a short-stem
secondary structure (Fig. 1). Melting of the secondary structure at high temperatures corre-
sponds to an increase of fluorescence by 16-fold. Cleavage by topoisomerase I in the loop re-
gion at three potential sites (P1, P2, P3) would destabilize the stem structure and increase the
fluorescence signal as well [6]. P1 was found to be the most preferred cleavage site for E. coli
topoisomerase I. For initial assay development, the FAM fluorophore was placed at the 5’-end
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and BHQ-1 quencher was placed at the 3’-end by custom synthesis (Sigma Genosys). Screening
of the NIH diversity set I compounds was carried out in 96-well black plate. The reaction mix-
ture of 100 nM oligo substrate, 100 nM Y. pestis topoisomerase I in 10 mM Tris-HCl (pH 8)
and 0.5 mMMgCl2 were dispensed in 100 μl aliquots, followed by addition of 1 μl of 10 mM
compounds or 1 μl DMSO as negative control. Following 30 min at 37°C, fluorescence (Ex/Em
wavelengths of 485/528 nm) was recorded with the BioTek Synergy HT plate reader. The assay
on the positive compounds was later repeated using an oligonucleotide substrate with CAL
Fluor Red 610 fluorophore at the 5’-end and BHQ-2 quencher at the 3’-end supplied by Bio-
search Technologies (Ex/Em wavelengths of 590/610 nm) to eliminate false positive signals
from compounds with autofluorescence in the same wavelength range as FAM. For follow up
dose-response experiments, compound concentrations varied between 50–800 μMwith
DMSO concentration kept at 1%.
Fig 1. Scheme of fluorescence assay to identify compounds that can increase the level of DNA cleavage product from bacterial topoisomerase I
due to increase in fluorescence emission from fluorophore. The structure shown is predicted by mfold [10], with constraints for the first and last bases be
paired to quench the emission from the fluorophore, and the cleavage sites P1, P2, P3 be in single-stranded region of the structure.
doi:10.1371/journal.pone.0120022.g001
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Gel based assay of oligonucleotide DNA cleavage product accumulation
The oligonucleotide substrate without the fluorophore or quencher was labeled at the 5’-end
with γ-32P-ATP and T4 polynucleotide Kinase. The labeled oligonucleotide (0.5 pmole) was in-
cubated with 100 ng of Y. pestis or E. coli topoisomerase I in 5 μL of 10 mM Tris-HCl, pH 8.0,
in the presence or absence of 2 mMMgCl2. Compound solutions or control DMSO was added
in 0.25 μl volumes. After incubation at 37°C for 30 min the reaction was terminated by the ad-
dition of an equal volume of sequencing gel loading buffer. The reaction substrate and products
were separated by electrophoresis in a 15% sequencing gel followed by Phosphor-Imager analy-
sis of the gel.
Relaxation activity assay
Supercoiled pBAD/Thio plasmid DNA substrate was purified by CsCl gradient centrifugation.
The relaxation reaction was carried out in 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.1 mg/mL
gelatin and 0.5 mMMgCl2. Compounds or DMSO (0.5 μl volume) were added to 10 μl of the
reaction mixture containing 250 ng of supercoiled DNA before combining with 10 μl of the re-
action mixture containing either 20 ng of E. coli topoisomerase I or 50 ng of Y. pestis topoisom-
erase I enzyme to initiate the relaxation reaction. Following incubation at 37°C for 30 min, the
reactions were terminated and analyzed by agarose gel electrophoresis as previously described
[11].
Non-covalent DNA binding assay
Non-covalent DNA binding by E. coli topoisomerase I was measured by a fluorescence anisot-
ropy assay as described previously [12] in binding buffer of 50 mM Tris–HCl, pH 7.5, 100 mM
NaCl, 0.1 mM EDTA, 0.5 mMMgCl2, with a 59-base oligonucleotide 5’-GCCCTGAAAGAT
TATGGAATGGGATTAGGGTAAAGGAAGAGAGCATAATCTTTCAGGGC-3’ that also
forms a stem-loop structure and has a 6-carboxyfluorescein modification at the 3’-end (sup-
plied by Biosearch Technologies). This substrate was shown in a previous report to bind with
high affinity to E. coli topoisomerase I, but cannot be cleaved by the enzyme due to the absence
of a cytosine in the single-stranded DNA region [12].
Results
Increase in fluorescence signal from organomercury compounds
identified in pilot screening of NIH Diversity Set I
A high-throughput screening assay was designed to identify inhibitors that can act as topo-
isomerase poisons for type IA topoisomerases. This assay utilizes an oligonucleotide substrate
with a 5’-fluorophore quenched by a 3’-quencher to produce an increase in fluorescence signal
from a higher level of oligonucleotide cleavage product produced by bacterial topoisomerase I
from the action of topoisomerase poison inhibitors. Y. pestis topoisomerase I was used in the
assay development due to its potential significance for bioterror concerns. The NIH Diversity
Set I of 1990 compounds was tested to identify potential positive control compounds during
assay development. Among the positive hits (compounds that increase the fluorescence signal
by 2 fold over DMSO negative control), there were two organomercury compounds,
NSC20410 and NSC268879 (Fig. 2A). Dose response of the effect of these compounds on the
increase in fluorescence signal were evaluated both in the presence of enzyme or absence of en-
zyme as a counter assay in order to eliminate compounds that did not produce enzyme-depen-
dent increase in fluorescence. The results (Fig. 2B) showed that the dose-dependent increase in
fluorescence signal from the addition of NSC20410 is entirely dependent on the presence of the
Topoisomerase IA Inhibition by Organomercury Compounds and Hg(II)
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topoisomerase I enzyme. Compound NSC268879 could cause an increase of fluorescence in
the absence of enzyme, but the level of fluorescence signal was further increased in the presence
of enzyme.
Inhibition of type IA topoisomerase relaxation activity by organomercury
compounds is dependent on presence of Zn(II)-binding cysteines
The relaxation activity of Y. pestis topoisomerase I was assayed using supercoiled pBAD/Thio
plasmid DNA as the substrate. Inhibition of the relaxation activity was observed as expected
(Fig. 3A). The IC50 for inhibition is between 20–30 μM for NSC20410 and is approximately
20 μM for NSC286679. Similar results (IC50 between 40–50 μM) were obtained for E. coli
topoisomerase I (Fig. 3B).
The increased accumulation of DNA cleavage product, as indicated by the fluorescence
assay, was confirmed for E. coli topoisomerase I with a gel-based assay using the same oligonu-
cleotide sequence from the fluorescence assay with the 32P-label introduced at the 5’-end of the
oligonucleotide substrate (Fig. 4). Analysis of the formation of the 5’-end labeled DNA cleavage
Fig 2. Organomercury hits from fluorescence based assay. A. Structures of organomercury hits from fluorescence based assay for increase in bacterial
topoisomerase I mediated oligonucleotide cleavage. B. Dose response of increase fluorescence reading (in arbitrary units) upon addition of the two hit
compounds (0.05–0.8 mM) in the absence (Δ) and presence (O) of Y. pestis topoisomerase I. Error bars correspond to standard deviations from at least three
sets of data.
doi:10.1371/journal.pone.0120022.g002
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reaction products showed that the presence of the organomercury compounds did not inhibit
the DNA cleavage step, but rather resulted in an overall increase in DNA cleavage (Fig. 4A). In
the absence of Mg(II), product P1 (5’-GTTATGCAATGCGCT) is the only major product ob-
served from the cleavage of the substrate by E. coli topoisomerase I, while P2 is a very minor
product (5’-GTTATGCAAT). The addition of the organomercury compounds resulted in the
significant increase of the cleavage product P2 (up to 8-fold increase from NSC20410 and
Fig 3. Inhibition of topoisomerase I relaxation activity by the organomercury compounds. A. Y. pestis topoisomerase I. B. E. coli topoisomerase I.
Assay was carried out in the presence of DMSO (C) or the indicated concentrations of compound added to the reaction mixture before the addition of
enzyme. No enz: no enzyme added. S: supercoiled pBAD/Thio DNA.
doi:10.1371/journal.pone.0120022.g003
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Fig 4. Effect of NSC20410 and NSC268879 on oligonucleotide cleavage product accumulation by E. coli topoisomerase I. A. Cleavage products (P1,
P2, P3) formed in the absence of Mg(II). E. coli topoisomerase I (ETOP) or its 67 KD N-terminal domain (ETOP67) was incubated with 5’-32P labeled
oligonucleotide substrate (O). Left panel: lane 1: substrate only control with no enzyme, lane 2: substrate incubated with ETOP in the presence of DMSO.
NSC20410 (lanes 3–5) and NSC268879 (lanes 6–8) were included in ETOP reactions at concentrations of 100, 10, 2 μM. Right panel: Comparison of
cleavage products formed by ETOP and ETOP67 with no inhibitors present. B. Inhibition of Mg(II)-mediated religation of DNA cleavage products NSC20410
and NSC268879. Products accumulated in the absence (-) or presence (+) of 2 mMMgCl2 were compared with control DMSO (lanes 2,3), 100 uM
NSC20410 (lanes 4,5) or 10 uM NSC268879 (lanes 6,7) added.
doi:10.1371/journal.pone.0120022.g004
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6-fold increase from NSC268879 when quantitated by densitometry analysis) and appearance
of another minor cleavage product P3 (5’ GTTATGCAATGCGCTTT), slightly longer in
length than product P1. This is consistent with the overall increase in DNA cleavage product
formation, with the shortest cleavage product, P2, being observed most readily. If cleavage
takes place at more than one site on a 5’-end labeled DNA substrate, then only the labeled
product corresponding to the cleavage site closest to the 5’-end will be observed [13, 14]. Inter-
estingly, the effect of these two organomercury compounds is similar to the effect of removal of
the 30 kDa C-terminal domain from the protein sequence as shown by the cleavage products
formed by ETOP67 (right hand panel of Fig. 4A), the 67 kDa N-terminal fragment of E. coli
topoisomerase I [15]. The presence of Mg(II) shifts the DNA cleavage-religation equilibrium of
E. coli topoisomerase I towards DNA religation, decreasing the amount of cleavage products.
This is evident from the densitometry analysis of the results shown in Fig. 4B, where in the
presence of Mg(II) (lane 3), cleavage products (P1, P2) are at 4% of the total oligonucleotide
substrate in comparison to 19% in the absence of Mg(II) (lane 4). However, densitometry anal-
ysis showed that the combined levels of the three cleavage products (P1, P2, P3) remaining fol-
lowing incubation with Mg(II) were 3-fold higher in the presence of the inhibitors NSC20410
(lane 5) or NSC268879 (lane 7) versus the DMSO control (lane 3). This indicates that the orga-
nomercury compounds inhibited DNA religation by E. coli topoisomerase I when Mg(II) was
present. The inhibition of religation of P2 cleavage product was observed most readily since it
corresponds to the cleavage site closest to the 5’-end label site.
The 30 kDa C-terminal domain of E. coli and Y. pestis topoisomerase I has three tetra-cyste-
ine zinc ribbon motifs that each bind a Zn(II) [16]. The Zn(II) ions can be replaced by Cd(II)
but not with other metal ions without loss of overall relaxation activity [17, 18]. Recombinant
E. coli topoisomerase with the zinc replaced by iron has been characterized and found to have
no activity on a DNA substrate [19]. The bacterial topoisomerase I enzymes share a highly ho-
mologous 67 kDa N-terminal transesterification domain [20]. However, the C-terminal do-
main can diverge significantly among the topoisomerase I enzymes from the different bacterial
species [20]. The topoisomerase I enzymes fromMycobacteria species have evolved to have a
C-terminal domain that lacks the zinc-binding tetra-cysteine motifs in E. coli and Y. pestis
topoisomerase I [21, 22]. The two organomercury compounds were found to have no effect on
the relaxation activity ofM. tuberculosis topoisomerase I (S1 Fig.). Increase in fluorescence was
also not observed in the fluorescence-based oligonucleotide cleavage assay usingM. tuberculo-
sis topoisomerase I. Dithiothreitol (DTT) was found to protect the relaxation activity of E. coli
topoisomerase I from inhibition by these organomercury compounds (Fig. 5). Therefore, the
cysteine residues that form the Zn(II)-binding motifs in the E. coli and Y. pestis topoisomerase
I are the likely target for the organomercury compounds identified in the screening assay.
Inhibition of relaxation activity by Hg(II) but not As(III)
Inorganic Hg(II) was also tested to see if it has a similar effect on these type IA topoisomerases
on its own without the bound organic ligand. Mercury chloride was found to inhibit the relaxa-
tion activity of both Y. pestis and E. coli topoisomerase I (Fig. 6A). In contrast, another known
zinc finger protein interacting metal such as Arsenic (III) [23] in the form of sodium meta arse-
nite (AsNaO2) at concentrations up to 10 mM did not have any effect on the relaxation activity
of E. coli topoisomerase I (S2 Fig.). Mercury chloride inhibited Y. pestis topoisomerase I slightly
more than E. coli topoisomerase I, similar to the results observed for the organomercury com-
pounds. Hg(II) also affected oligonucleotide cleavage by E. coli topoisomerase I in similar man-
ners as the organomercury compounds. Hg(II) increased the relative level of the shortest 5’-
end labeled cleavage product P2 over the longer cleavage product P1 (Fig. 6B). Similar to the
Topoisomerase IA Inhibition by Organomercury Compounds and Hg(II)
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organomercury compounds, densitometry analysis showed that in the absence of Mg(II) there
is a significant increase in the shortest cleavage product P2 in lanes 3–5 (up to 10-fold when
compared with the lane 2 containing no compound). Also, similar to results shown in Fig. 4B
there is a shift towards DNA religation in the presence of 2 mMMg (II), resulting in lesser
combined cleavage products in lane 7 compared to lane 6 without Mg (II). HgCl2 concentra-
tions between 5–100 μM, when incubated with Mg (II), resulted in up to 2-fold increase in
combined cleavage products (lanes 8–10) when compared to the no HgCl2 reaction (lane 7).
This result indicates that Hg(II) preferentially inhibits DNA religation by these type IA topo-
isomerases and increases the level of DNA cleavage. The increase in DNA cleavage caused by
NSC20410 and Hg(II) is not due to increase in DNA binding affinity. The measurement of
non-covalent binding by an anisotropy assay (Fig. 7) showed that the presence of NSC20410 or
HgCl2 had only a minor effect on the non-covalent binding to DNA, with nearly identical max-
imal anisotropy and a less than 1-fold effect on the dissociation constant Kd.
Discussion
Bacterial topoisomerase I is a potentially useful target for the discovery of much needed new
leads for antibacterial therapeutics that can be used to treat drug resistant pathogens [3]. Topo-
isomerase poison inhibitors that can increase the DNA cleavage intermediates formed by type
IA topoisomerases with the required selectivity still remain to be identified [4]. Such type IA
topoisomerase poison inhibitors are expected to be bactericidal based on the study of bacterial
topoisomerase I mutants deficient in DNA religation following DNA cleavage [7, 24]. During
assay development of a HTS assay for identifying potential poison inhibitors against Y. pestis
topoisomerase I, two organomercury compounds in the NIH Diversity Set I of compounds
were found in the pilot screening to increase the level of DNA cleavage products formed by Y.
pestis topoisomerase I. Gel-based assays confirmed that these compounds did not prevent
Fig 5. Protection of topoisomerase relaxation activity inhibition by DTT. No Enz: no enzyme. E. coli
topoisomerase I (50 ng) were present in all the other lanes. C: DMSO control. Compounds and DTT were
present at 50 μM. S: supercoiled pBAD/Thio plasmid DNA.
doi:10.1371/journal.pone.0120022.g005
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Fig 6. Effect of mercury chloride on Y. pestis and E. coli topoisomerase I activity. A. Assay of inhibition of relaxation activity of Y. pestis (YTOP) and E.
coli topoisomerase I (ETOP). S: Supercoiled pBAD/Thio plasmid DNA. B. Mercury chloride does not abolish DNA cleavage by ETOP and increases the yield
of the shortest ETOP cleavage product both in the absence and presence of Mg(II). Oligonucleotide substrate (O) and cleavage products (P1, P2, P3) from E.
coli topoisomerase I with no MgCl2 (lanes 2–6), or 2 mMMgCl2 (lanes 7–10) were analyzed. Lane 1: no enzyme control. HgCl2 is present at 0 μM (lanes
2,6,7), 5 μM (lanes 5, 10), 10 μM (lanes 4, 9) and 100 μM (lanes 3, 8). The lanes shown are from the same PhosphorImager gel record.
doi:10.1371/journal.pone.0120022.g006
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oligonucleotide DNA cleavage, but rather increased the level of the accumulation of the DNA
cleavage products. These two compounds inhibited the relaxation activity of E. coli and Y. pestis
topoisomerase I, but had no effect on the activity ofM. tuberculosis topoisomerase I, which
does not have Zn(II)-binding tetra-cysteine motifs for the C-terminal domain function [22].
The protective effect of DTT, and similar inhibitory actions of inorganic mercury chloride indi-
cated that the zinc-binding cysteines in E. coli and Y. pestis topoisomerase I are vulnerable to
interference by organomercury and inorganic mercury compounds. The IC50s for inhibition
by Hg(II) are about ten-fold lower than the IC50s for the organomercury compounds. The
topoisomerase I cysteines in the C-terminal may be more accessible to Hg(II) than the organo-
mercury compounds. Furthermore, NSC20410 had little effect on the DNA substrate fluores-
cence in the absence of enzyme in contrast to NSC268879 which can result in an increase of
fluorescence in the absence of enzyme (Fig. 2B). Hg(II) and NSC20410 are likely to target with
binary selectivity the Zn(II)-binding cysteines in the C-terminal domain of the enzyme for co-
ordination by Hg(II), while NSC268879 might interact with both the enzyme and DNA in its
mechanism of action. This difference in mechanism of inhibition may account for the more
gradual relaxation inhibition observed as NSC268879 concentration increases (Fig. 3).
Mutations of bacterial topoisomerase I shown previously to inhibit DNA religation were all
found in the N-terminal domain at the Mg(II) binding TOPRIM residues [7, 24] or surround-
ing the active site tyrosine [8, 25]. The C-terminal domains of type IA topoisomerases are
known to play critical roles in interactions with DNA and other cellular proteins relevant to
Fig 7. Noncovalent DNA binding by E. coli topoisomerase I in the absence and presence of NSC20410
andmercury chloride as determined by DNA fluorescence anisotropy.Graphs showing anisotropy
change observed when DNA substrate with 6-carboxyfluorescein modification at 3’-end (30 nM) was titrated
with increasing concentrations of E. coli topoisomerase I in the absence of inhibitor (red triangles), or in the
presence of 45 μMNSC20410 (green circles), or 5 μMmercury chloride (blue squares). The Kd (dissociation
constant) values were calculated from fitting of the anisotropy data from 10, 20 and 30 nM oligonucleotide
concentrations as described previously [12].
doi:10.1371/journal.pone.0120022.g007
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their catalytic activities and physiological functions. The Zn(II)-binding domain of E. coli topo-
isomerase I [15] has been postulated to interact with DNA to promote strand passage for the
relaxation of negative supercoils. Site-directed mutations in the Zn(II) coordinating cysteines
of E. coli topoisomerase I have been shown to affect DNA cleavage sequence selectivity and can
lead to a significant loss of relaxation activity [26]. The Zn(II)-binding domain of E. coli topo-
isomerase I has also been shown to be important for direct protein-protein interaction with the
RNA polymerase β’ subunit [27] for relief of transcription-driven supercoiling. This protein-
protein interaction helps to prevent inhibition of transcription elongation due to hypernegative
supercoiling and resulting R-loops of RNA-DNA hybrids [28]. The C-terminal domain of Dro-
sophila topoisomerase IIIα, a type IA topoisomerase with multiple Zn(II)-binding CCCC mo-
tifs, is required for the function of the enzyme in double Holliday junction resolution [29].
It should be noted that the organomercury compounds and Hg(II) did not inhibit the DNA
cleavage step of the Zn(II)-binding type IA topoisomerases tested, but rather affected the sub-
sequent step of DNA rejoining. Accumulation of topoisomerase cleavage complexes from the
action of topoisomerase poison inhibitors has been linked to genomic translocations and carci-
nogenesis [30]. Human type IA topoisomerases, including human Top3α and Top3β, play im-
portant roles in genomic stability [31] and neuronal development respectively [32, 33] as part
of multi-protein complexes that interact with DNA as well as RNA. Human Top3α and Top3β
each have multiple units of CCCC zinc ribbon motifs in their C-terminal domains. Trivalent
As(III) has been shown to interact selectively with zinc finger proteins containing CCCH or
CCCCmotifs [23] that accounts, at least in part, for the carcinogenic and toxic effect of arsenite
[34]. As(III) however had no effect on the activity of the CCCC zinc ribbon motifs of the bacte-
rial type IA topoisomerases tested here, probably due to the difference in coordination chemis-
try and geometry. Organomercury or Hg(II) may have adverse effects on protein-protein and
protein-DNA interactions of involving similar CCCC zinc ribbon motifs in the C-terminal do-
mains of human type IA topoisomerases. There might be harmful consequence on human
health if covalent complexes between topoisomerase and cleaved DNA become stabilized dur-
ing chromosomal DNA cleavage-rejoining of the topoisomerase catalytic cycle.
Conclusions
Organomercury compounds and inorganic mercury ions can inhibit the relaxation activity of
type IA bacterial topoisomerases with Zn(II)-binding cysteines in their C-terminal domains
and lead to the accumulation of DNA cleavage products.
Supporting Information
S1 Fig. Organomercury compounds had no significant effect on the relaxation activity of
M. tuberculosis topoisomerase I.
(PDF)
S2 Fig. Testing of As(III) for inhibition of E. coli topoisomerase I relaxation activity.
(PDF)
Acknowledgments
We acknowledge the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov) for supply
of compounds used in this study.
Topoisomerase IA Inhibition by Organomercury Compounds and Hg(II)
PLOS ONE | DOI:10.1371/journal.pone.0120022 March 23, 2015 12 / 14
Author Contributions
Conceived and designed the experiments: YT. Performed the experiments: BC TA SS PB. Ana-
lyzed the data: BC TA SS PB YT. Contributed reagents/materials/analysis tools: BC TA. Wrote
the paper: BC TA SS YT.
References
1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;
3: 430–440. PMID: 12042765
2. Vos SM, Tretter EM, Schmid BH, Berger JM. All tangled up: how cells direct, manage and exploit topo-
isomerase function. Nat Rev Mol Cell Biol. 2011; 12: 827–841. doi: 10.1038/nrm3228 PMID: 22108601
3. Tse-Dinh YC. Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic
Acids Res. 2009; 37: 731–737. doi: 10.1093/nar/gkn936 PMID: 19042977
4. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013; 8: 82–95. doi:
10.1021/cb300648v PMID: 23259582
5. Aedo S, Tse-Dinh YC. Isolation and quantitation of topoisomerase complexes accumulated on Escheri-
chia coli chromosomal DNA. Antimicrob Agents Chemother. 2012; 56: 5458–5464. doi: 10.1128/AAC.
01182-12 PMID: 22869559
6. Cheng B, Cao S, Vasquez V, Annamalai T, Tamayo-Castillo G, Clardy J, et al. Identification of anziaic
acid, a lichen depside from Hypotrachyna sp., as a new topoisomerase poison inhibitor. PLoS One
2013; 8: e60770. doi: 10.1371/journal.pone.0060770 PMID: 23593306
7. Cheng B, Shukla S, Vasunilashorn S, Mukhopadhyay S, Tse-Dinh YC. Bacterial cell killing mediated by
topoisomerase I DNA cleavage activity. J. Biol. Chem. 2005; 280: 38489–38495. PMID: 16159875
8. Sorokin EP, Cheng B, Rathi S, Aedo SJ, Abrenica MV, Tse-Dinh YC. Inhibition of Mg2+ binding and
DNA religation by bacterial topoisomerase I via introduction of an additional positive charge into the ac-
tive site region. Nucleic Acids Res. 2008; 36:4788–4796. doi: 10.1093/nar/gkn460 PMID: 18653534
9. Annamalai T, Dani N, Cheng B, Tse-Dinh YC. Analysis of DNA relaxation and cleavage activities of re-
combinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification
protocol. BMC Biochem. 2009; 10: 18. doi: 10.1186/1471-2091-10-18 PMID: 19519900
10. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res.
2003; 31: 3406–3415. PMID: 12824337
11. Zhu CX,Tse-Dinh, Tse-Dinh YC. The acidic triad conserved in type IA DNA topoisomerases is required
for binding of Mg(II) and subsequent conformational change. J Biol Chem. 2000; 275: 5318–5322.
PMID: 10681504
12. Narula G, Tse-Dinh YC. Residues of E. coli topoisomerase I conserved for interaction with a specific cy-
tosine base to facilitate DNA cleavage. Nucleic Acids Res. 2012; 40: 9233–9243. doi: 10.1093/nar/
gks688 PMID: 22833607
13. Jaxel C, Duguet M, Nadal M. Analysis of DNA cleavage by reverse gyrase from Sulfolobus shibatae
B12. Eur J Biochem. 1999; 260: 103–111. PMID: 10091589
14. Karlovsky P. Re-evaluation of a method calculating cleavage rates at different sites of DNA from partial
digestion of end-labelled molecule. Biochem Biophys Res Commun. 1986; 138: 778–782. PMID:
3017337
15. Ahumada A, Tse-Dinh YC. The role of the Zn(II) binding domain in the mechanism of E. coli DNA topo-
isomerase I. BMC Biochem. 2002; 3: 13. PMID: 12052259
16. Grishin NV. C-terminal domains of Escherichia coli topoisomerase I belong to the zinc-ribbon superfam-
ily. J Mol Biol. 2000; 299: 1165–1177. PMID: 10873443
17. Tse-Dinh YC. Zinc (II) coordination in Escherichia coli DNA topoisomerase I is required for cleavable
complex formation with DNA. J Biol Chem. 1991; 266: 14317–14320. PMID: 1650356
18. Tse-Dinh YC, Beran-Steed RK. Escherichia coli DNA topoisomerase I is a zinc metalloprotein with
three repetitive zinc-binding domains. J Biol Chem. 1988; 263: 15857–15859. PMID: 2846526
19. Lu J, WangW, Tan G, Landry AP, Yi P, Si F, Ren Y, Ding H. Escherichia coli topoisomerase I is an iron
and zinc binding protein. Biometals 2011; 24: 729–736. doi: 10.1007/s10534-011-9425-6 PMID:
21347852
20. Viard T, de la Tour CB. Type IA topoisomerases: a simple puzzle? Biochimie 2007;bh 89: 456–467.
PMID: 17141394
21. Bhaduri T, Bagui TK, Sikder D, Nagaraja V. DNA topoisomerase I fromMycobacterium smegmatis. An
enzyme with distinct features. J Biol Chem. 1998; 273: 13925–13932. PMID: 9593741
Topoisomerase IA Inhibition by Organomercury Compounds and Hg(II)
PLOS ONE | DOI:10.1371/journal.pone.0120022 March 23, 2015 13 / 14
22. AhmedW, Bhat AG, LeelaramMN, Menon S, Nagaraja V. Carboxyl terminal domain basic amino acids
of mycobacterial topoisomerase I bind DNA to promote strand passage. Nucleic Acids Res. 2013;
41:7462–7471. doi: 10.1093/nar/gkt506 PMID: 23771144
23. Zhou X, Sun X, Cooper KL, Wang F, Liu KJ, Hudson LG. Arsenite interacts selectively with zinc finger
proteins containing C3H1 or C4 motifs. J Biol Chem. 2011; 286: 22855–22863. doi: 10.1074/jbc.M111.
232926 PMID: 21550982
24. Cheng B, Annamalai T, Sorokin E, Abrenica M, Aedo S, Tse-Dinh YC. Asp-to-Asn substitution at the
first position of the DxD TOPRIMmotif of recombinant bacterial topoisomerase I is extremely lethal to E.
coli. J Mol Biol. 2009; 385: 558–567. doi: 10.1016/j.jmb.2008.10.073 PMID: 19013470
25. Cheng B, Sorokin EP, Tse-Dinh YC. Mutation adjacent to the active site tyrosine can enhance DNA
cleavage and cell killing by the TOPRIMGly to Ser mutant of bacterial topoisomerase I. Nucleic Acids
Res. 2008; 36: 1017–1025. PMID: 18096618
26. Zhu CX, Qi HY, Tse-Dinh YC. Mutation in Cys662 of Escherichia coliDNA topoisomerase I confers tem-
perature sensitivity and change in DNA cleavage selectivity. J Mol Biol. 1995; 50: 609–616.
27. Cheng B, Zhu CX, Ji C, Ahumada A, Tse-Dinh YC. Direct interaction between Escherichia coli RNA po-
lymerase and the zinc ribbon domains of DNA topoisomerase I. J Biol Chem. 2003; 278: 30705–30710.
PMID: 12788950
28. Drolet M. Growth inhibition mediated by excess negative supercoiling: the interplay between transcrip-
tion elongation, R-loop formation and DNA topology. Mol Microbiol. 2006; 59: 723–730. PMID:
16420346
29. Chen SH, Wu CH, Plank JL, Hsieh TS. Essential functions of C terminus of Drosophila Topoisomerase
IIIalpha in double holliday junction dissolution. J Biol Chem. 2012; 287: 19346–19353. doi: 10.1074/jbc.
M112.363044 PMID: 22511792
30. Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk-Lesthuruge M, et al. Model for MLL
translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks
and gene proximity. Proc Natl Acad Sci U S A. 2012; 109: 8989–8994. doi: 10.1073/pnas.1204406109
PMID: 22615413
31. Yang J, Bachrati CZ, Ou J, Hickson ID, Brown GW. Human topoisomerase IIIalpha is a single-stranded
DNA decatenase that is stimulated by BLM and RMI1. J. Biol. Chem. 2010; 285: 21426–21436. doi: 10.
1074/jbc.M110.123216 PMID: 20445207
32. Stoll G, Pietiläinen OP, Linder B, Suvisaari J, Brosi C, HennahW, et al. Deletion of TOP3beta, a compo-
nent of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat Neurosci. 2013;
16: 1228–1237. doi: 10.1038/nn.3484 PMID: 23912948
33. Xu D, ShenW, Guo R, Xue Y, PengW, Sima J, et al. Top3beta is an RNA topoisomerase that works
with fragile X syndrome protein to promote synapse formation. Nat Neurosci. 2013; 16: 1238–1247.
doi: 10.1038/nn.3479 PMID: 23912945
34. Kitchin KT, Wallace K. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and
toxicity. J Inorg Biochem. 2008; 102: 532–539. doi: 10.1016/j.jinorgbio.2007.10.021 PMID: 18164070
Topoisomerase IA Inhibition by Organomercury Compounds and Hg(II)
PLOS ONE | DOI:10.1371/journal.pone.0120022 March 23, 2015 14 / 14
